CN102065888B - 抗-vegf抗体 - Google Patents

抗-vegf抗体 Download PDF

Info

Publication number
CN102065888B
CN102065888B CN200880128968.5A CN200880128968A CN102065888B CN 102065888 B CN102065888 B CN 102065888B CN 200880128968 A CN200880128968 A CN 200880128968A CN 102065888 B CN102065888 B CN 102065888B
Authority
CN
China
Prior art keywords
antibody
amino acid
antibodies
region
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880128968.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102065888A (zh
Inventor
柯耀煌
朱伟民
余国良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitomics Inc
Original Assignee
Epitomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitomics Inc filed Critical Epitomics Inc
Priority to CN201410106341.7A priority Critical patent/CN103992405B/zh
Publication of CN102065888A publication Critical patent/CN102065888A/zh
Application granted granted Critical
Publication of CN102065888B publication Critical patent/CN102065888B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200880128968.5A 2008-03-26 2008-10-08 抗-vegf抗体 Active CN102065888B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410106341.7A CN103992405B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3971908P 2008-03-26 2008-03-26
US61/039,719 2008-03-26
PCT/US2008/011620 WO2009120178A1 (en) 2008-03-26 2008-10-08 Anti-vegf antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410106341.7A Division CN103992405B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Publications (2)

Publication Number Publication Date
CN102065888A CN102065888A (zh) 2011-05-18
CN102065888B true CN102065888B (zh) 2014-03-26

Family

ID=41114205

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880128968.5A Active CN102065888B (zh) 2008-03-26 2008-10-08 抗-vegf抗体
CN201410106341.7A Active CN103992405B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410106341.7A Active CN103992405B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Country Status (9)

Country Link
US (2) US7803371B2 (enExample)
EP (1) EP2259795B1 (enExample)
JP (2) JP5823858B2 (enExample)
KR (1) KR101581244B1 (enExample)
CN (2) CN102065888B (enExample)
AU (1) AU2008353479B2 (enExample)
BR (1) BRPI0822556B1 (enExample)
CA (3) CA2719400C (enExample)
WO (1) WO2009120178A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2307454T (pt) 2008-06-25 2017-04-26 Esbatech Alcon Biomed Res Unit Anticorpos estáveis e solúveis que inibem o vegf
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
WO2011047442A1 (en) * 2009-10-23 2011-04-28 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
BR112013021863A2 (pt) 2011-03-03 2016-11-22 Apexigen Inc anticorpos anti-receptor il-6 e métodos de uso
CN104650229A (zh) * 2011-11-02 2015-05-27 埃派斯进有限公司 抗-kdr抗体和使用方法
CN103417964A (zh) * 2012-05-17 2013-12-04 江苏先声药物研究有限公司 一种抗vegf抗体的用途
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
JP2016530244A (ja) * 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 抗ｖｅｇｆ抗体及びその使用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US20180142038A1 (en) * 2015-01-16 2018-05-24 ALDER BIOPHARMACEUTICALS, INC. a/b/a ALDERBIO HOLDINGS LLC Anti-glycoprotein antibodies and uses thereof
CN107849105B (zh) * 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
KR20220093103A (ko) * 2019-09-13 2022-07-05 어드메어 테라퓨틱스 소사이어티 항종양용해 바이러스 항원 항체 및 이의 사용 방법
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL321781A (en) * 2022-12-29 2025-08-01 Ltz Therapeutics Inc Anti-cd79b antibodies and uses thereof
CN118344476B (zh) * 2024-05-16 2024-11-15 武汉爱博泰克生物科技有限公司 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1839144A (zh) * 2003-08-07 2006-09-27 宜康公司 兔单克隆抗体的人源化方法
US20060216293A1 (en) * 2005-03-24 2006-09-28 Couto Fernando J R TNFalpha-neutralizing antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308347C (zh) * 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
CN1299833A (zh) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 抗人血管内皮生长因子单链抗体及其制备方法
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
JP2005535341A (ja) * 2002-08-15 2005-11-24 エピトミスク インコーポレーティッド ヒト化ウサギ抗体
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
KR101834797B1 (ko) * 2008-06-25 2018-03-07 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1839144A (zh) * 2003-08-07 2006-09-27 宜康公司 兔单克隆抗体的人源化方法
US20060216293A1 (en) * 2005-03-24 2006-09-28 Couto Fernando J R TNFalpha-neutralizing antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
廖楚航等.抗人VEGF单链抗体基因的克隆及突变校正.《实用医院临床杂志》.2004,第1卷(第01期),26-29. *
抗人VEGF单链抗体基因的克隆及突变校正;廖楚航等;《实用医院临床杂志》;20040131;第1卷(第01期);26-29 *
抗人VEGF受体Ⅱ基因Ⅲ区单链抗体基因的构建和表达;李容等;《生物工程学报》;20040331;第20卷(第02期);187-191 *
李容等.抗人VEGF受体Ⅱ基因Ⅲ区单链抗体基因的构建和表达.《生物工程学报》.2004,第20卷(第02期),187-191. *

Also Published As

Publication number Publication date
HK1201280A1 (en) 2015-08-28
CN102065888A (zh) 2011-05-18
CA2981887A1 (en) 2009-10-01
AU2008353479B2 (en) 2014-02-20
CN103992405B (zh) 2016-08-17
CA2719400A1 (en) 2009-10-01
US7803371B2 (en) 2010-09-28
BRPI0822556A2 (pt) 2020-08-18
JP2014205674A (ja) 2014-10-30
CA3053675A1 (en) 2009-10-01
US20090246190A1 (en) 2009-10-01
EP2259795A4 (en) 2012-06-06
JP5823858B2 (ja) 2015-11-25
EP2259795A1 (en) 2010-12-15
WO2009120178A1 (en) 2009-10-01
BRPI0822556B1 (pt) 2022-03-03
US8088375B2 (en) 2012-01-03
US20110008367A1 (en) 2011-01-13
JP2011517447A (ja) 2011-06-09
CA2719400C (en) 2017-11-14
KR20100132983A (ko) 2010-12-20
KR101581244B1 (ko) 2015-12-31
AU2008353479A1 (en) 2009-10-01
CA2981887C (en) 2019-09-03
CN103992405A (zh) 2014-08-20
EP2259795B1 (en) 2016-04-06

Similar Documents

Publication Publication Date Title
CN102065888B (zh) 抗-vegf抗体
JP5513888B2 (ja) グルカゴン受容体抗体に関する組成物および方法
CN109071654B (zh) 靶向Fc受体样5的抗体及使用方法
JP5738294B2 (ja) 抗ｖｅｇｆモノクローナル抗体およびその抗体を含む薬学的組成物
JP2021531826A (ja) 栄養膜細胞表面抗原２（ｔｒｏｐ２）に対する特異的な抗体
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
EP4386004A1 (en) Anti-vegf a and -vegf c bispecific antibody and use thereof
CN119698434A (zh) 抗gprc5d纳米抗体及其应用
AU2014202474B2 (en) Anti-VEGF antibody
JP7564882B2 (ja) Ａｒｅｇに対する抗体及びその用途
HK1201280B (en) Anti-vegf antibody
CN117244055A (zh) Cd70抗体的药物组合物及其应用
WO2024002145A1 (zh) 结合il-17a和il-17f的抗体分子及其应用
CN119350502A (zh) 靶向fap的抗原结合蛋白及其应用
CN119264255A (zh) 抗人cd70抗体及其应用
WO2017125601A1 (en) Anti-bsep-specific antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant